Liposomal Doxorubicin Market Size, Share, and Growth Analysis, By Product Type (Lipodox, Doxil), By Application (Breast Cancer, Ovarian Cancer), By Distribution Channel, By Region - Industry Forecast 2025-2032
세계의 리포솜 독소루비신 시장 규모는 2023년에 12억 달러로 평가되며, 2024년 12억 8,000만 달러에서 2032년에는 21억 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 6.4%로 성장할 전망입니다.
리포솜 독소루비신 시장은 육종 발병률 증가와 유방암, 난소암, 카포시육종 등 다양한 암 치료에 약물이 사용됨에 따라 강력한 성장세를 보이고 있습니다. 리포솜에 담긴 이 화학요법 솔루션은 현대 의료의 발전, 의료비 증가, 치료 옵션에 대한 환자들의 인식이 높아짐에 따라 혜택을 받고 있습니다. 제네릭 의약품과의 경쟁과 FDA의 까다로운 승인 절차가 도전이 되고 있지만, 공공 및 민간 부문의 투자 확대로 전체 시장이 확대될 것으로 예상됩니다. 또한 간세포암의 이환율과 생존율 증가, 기존 치료에 반응하지 않는 환자들을 위한 효과적인 대체요법에 대한 요구가 증가함에 따라 리포좀 독소루비신에 대한 수요를 더욱 자극하여 향후 수년간 시장이 크게 성장할 것으로 예상됩니다.
목차
서론
조사 방법
- 정보 조달
- 2차와 1차 데이터 방법
- 시장 규모 예측
- 시장의 전제조건과 제한
개요
- 세계 시장 전망
- 공급과 수요 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porter의 산업 분석
주요 시장 인사이트
- 주요 성공 요인
- 경쟁의 정도
- 주요 투자 기회
- 시장 에코시스템
- 시장의 매력 지수(2024년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
- 사례 연구
- 규제 상황
- 특허 분석
리포솜 독소루비신 시장 규모 : 제품 유형별 & CAGR(2025-2032)
- 시장 개요
- Lipodox
- Doxil
- Myocet
리포솜 독소루비신 시장 규모 : 용도별 & CAGR(2025-2032)
- 시장 개요
- 유방암
- 난소암
- 다발성골수종
- 카포시육종
- 기타 암
리포솜 독소루비신 시장 규모 : 유통 채널별 & CAGR(2025-2032)
리포솜 독소루비신 시장 규모 : 지역별 & CAGR(2025-2032)
- 북미
- 유럽
- 독일
- 스페인
- 프랑스
- 영국
- 이탈리아
- 기타 유럽 지역
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
경쟁 정보
- 상위 5사의 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채택한 전략
- 최근 시장 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업의 기업 개요
- 기업의 상세
- 제품 포트폴리오 분석
- 기업의 부문별 점유율 분석
- 매출의 전년대비 비교(2022-2024)
주요 기업 개요
- Johnson & Johnson(USA)
- Sun Pharmaceutical Industries Ltd.(India)
- Pfizer Inc.(USA)
- Merck & Co., Inc.(USA)
- Cipla Inc.(India)
- Cadila Pharmaceuticals(India)
- SRS Pharmaceuticals Pvt. Ltd.(India)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Gilead Sciences, Inc.(USA)
- Baxter International Inc.(USA)
- Novartis AG(Switzerland)
- F. Hoffmann-La Roche AG(Switzerland)
- Bristol-Myers Squibb Company(USA)
- Mylan N.V.(USA)
- Sanofi S.A.(France)
- Eli Lilly and Company(USA)
- GlaxoSmithKline plc(UK)
- AstraZeneca plc(UK)
- Amgen Inc.(USA)
- Takeda Pharmaceutical Company Limited(Japan)
결론과 제안
KSA
Global Liposomal Doxorubicin Market size was valued at USD 1.2 billion in 2023 and is poised to grow from USD 1.28 billion in 2024 to USD 2.1 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).
The liposomal doxorubicin market is experiencing robust growth driven by the rising incidence of sarcoma and the drug's use in treating various cancers such as breast, ovarian, and Kaposi sarcoma. This chemotherapy solution, encapsulated in liposomes, benefits from modern healthcare advancements, increased healthcare expenditures, and heightened patient awareness regarding treatment options. While competition from generic medications and stringent FDA approval processes pose challenges, overall market expansion is anticipated due to growing investment from both public and private sectors. Additionally, the escalating need for effective alternatives for patients unresponsive to traditional treatments, alongside the rising incidence and survival rates of hepatocellular carcinoma, further stimulates demand for liposomal doxorubicin, positioning the market for substantial growth in the coming years.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liposomal Doxorubicin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Liposomal Doxorubicin Market Segments Analysis
Global Liposomal Doxorubicin Market is segmented by Product Type, Application, Distribution Channel and region. Based on Product Type, the market is segmented into Lipodox, Doxil and Myocet. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, Multiple Myeloma, Kaposi's Sarcoma and Other Cancers. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Liposomal Doxorubicin Market
The Global Liposomal Doxorubicin market is predominantly driven by its application in the treatment of breast cancer, a disease that is rapidly escalating in prevalence across the globe. The surge in innovative formulations has significantly enhanced the drug's appeal and adoption for breast cancer therapy. Several other factors are expected to propel market growth in the coming years, including a rising demand for targeted therapies, increased utilization of chemotherapy, and heightened investments from private sectors focused on this treatment. Additionally, robust government support for the healthcare industry plays a vital role in advancing the market's global expansion.
Restraints in the Global Liposomal Doxorubicin Market
The global liposomal doxorubicin market could face limitations due to potential adverse effects associated with the medication. Patients may experience various complications such as an increased risk of infections, difficulty in breathing, pallor, unexplained bruising, frequent nosebleeds, fatigue, and weakness both prior to and following treatment. Additionally, symptoms such as painful red or peeling skin on the hands and feet, significant weight loss, diarrhea, and generalized weariness may arise. These side effects could result in hesitancy among patients and healthcare providers, ultimately restraining the market's growth and acceptance in the treatment landscape.
Market Trends of the Global Liposomal Doxorubicin Market
The Global Liposomal Doxorubicin market is witnessing significant growth, driven primarily by the increasing incidence of breast cancer, which accounts for one in four female cancer diagnoses globally, according to the International Agency for Research on Cancer (IARC). As liposomal formulations enhance the therapeutic efficacy and reduce the cardiotoxicity associated with conventional doxorubicin, they are gaining traction among oncologists and patients alike. Innovations in drug delivery systems, coupled with rising healthcare expenditures and a surge in awareness regarding targeted cancer therapies, position liposomal doxorubicin as a preferred choice in chemotherapeutic regimens, effectively meeting the growing demand for safer and more effective cancer treatments worldwide.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Case Studies
- Regulatory Landscape
- Patent Analysis
Global Liposomal Doxorubicin Market Size by Product Type & CAGR (2025-2032)
- Market Overview
- Lipodox
- Doxil
- Myocet
Global Liposomal Doxorubicin Market Size by Application & CAGR (2025-2032)
- Market Overview
- Breast Cancer
- Ovarian Cancer
- Multiple Myeloma
- Kaposi's Sarcoma
- Other Cancers
Global Liposomal Doxorubicin Market Size by Distribution Channel & CAGR (2025-2032)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Liposomal Doxorubicin Market Size & CAGR (2025-2032)
- North America (Product Type, Application, Distribution Channel)
- Europe (Product Type, Application, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product Type, Application, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product Type, Application, Distribution Channel)
- Brazil
- Rest of Latin America
- Middle East & Africa (Product Type, Application, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Inc. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cadila Pharmaceuticals (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- SRS Pharmaceuticals Pvt. Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
